| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -50.4 | -41.4 |
| EPS (diluted, $ a share) | $-0.15 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ALLO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Allogene Therapeutics, Inc.: key numbers
- Share price
- $0.8070Close, Nov 16
- Market cap
- $280M
- Shares outstanding
- 346.47MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Allogene Therapeutics, Inc.
All →Allogene Therapeutics Financial Results
Allogene Therapeutics reported financial results for the third quarter of 2026, ending the period with $388.9 million in cash and investments. The company highlighted enrollment momentum in its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL and upcoming data presentations for its autoimmune candidate ALLO-329.
- Term
- Q3 2026
“We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer
“Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”
Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer